You searched for "MET"
Preparing for the FRCS (Urol) viva
Ping! You look down to your phone and you have just received an email saying, “Congratulations, you have now successfully completed The Joint Committee on Intercollegiate Examinations section 1 of the Fellowship of the Royal College of Surgeons (Urol) exam.”...Demanding cases or nightmares in uro-oncology? Jan/Feb 2022
When less is more: percutaneous biopsy and tumour seeding in papillary renal cell carcinoma Renal cell carcinoma (RCC) accounted for 2.2% of new cancer diagnoses worldwide in 2018 with over 400,000 new cases and 175,098 deaths [1]. The majority of...Prostate artery embolisation
Introduction Benign prostatic hyperplasia (BPH), a common condition associated with ageing, affects 50% of those between the ages of 50 and 60 years, and as many as 90% of those older than 80 years. BPH is characterised by unregulated, benign...TUF Warriors – joining the fundraising fight
What is the TUF Warrior programme? The Urology Foundation (TUF) Warrior programme is designed to support core trainees, clinical fellows and foundation doctors interested in urology. It creates opportunities to develop extracurricular interests, connect with patients, boost applications for specialty...Urinary biomarkers for surveillance of non-muscle invasive bladder cancer
Bladder cancer (BC) is the ninth most common cancer worldwide with a yearly incidence of approximately 430,000 cases. There is a male predominance and it is the seventh most common cancer in men worldwide [1]. Non-muscle invasive bladder cancer (NMIBC)...Recent developments in bladder cancer – MIBC
This article takes a look back over recent years at new innovations and developments relating to muscle-invasive bladder cancer (MIBC) specifically, and will also touch upon what the future may hold. This article is also written as a continuation of...
First and second-line treatments in metastatic renal cell carcinoma
Over the past two decades, the treatment landscape for metastatic renal cell carcinoma (mRCC) has evolved significantly, leading to a quadrupling of patient survival rates. Modern systemic treatments include combinations of anti-PD-1 antibodies with either anti-CTLA-4 antibodies or antiangiogenic tyrosine...Advanced Twitter
It has been a few years since my post on ‘Twitter for urologists’ was published in Urology News [1]. Given the continued rise of the platform, I thought it was time to revisit and expand on Twitter’s functionality. In this...Intravesical glycosaminoglycan analogue instillations for recurrent cystitis
Introduction The symptoms of recurrent cystitis can be triggered by inflammatory or infective causes. Bladder pain syndrome (BPS) and bacterial recurrent lower urinary tract infection can both present with symptoms of recurrent cystitis and cause significant morbidity in affected individuals....In conversation with Ahmed Ali
We were delighted to chat to Ahmed Ali about the journey to pursing a urological career in the UK and his decision to found the Arabic-British Urological Society. You grew up in Iraq and went to university in Baghdad; what...My experience of addiction
In this incredibly honest and thought-provoking article, we hear from an anonymous doctor who has struggled with addiction. The nature of addiction is a subject of interest to a broad range of scientific disciplines, from medicine to psychology, psychotherapy and...
